Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer

Abstract Background Selinexor (KPT-330) is an oral agent that has been shown to inhibit the nuclear exporter XPO1. Given the pressing need for novel therapies for triple-negative breast cancer (TNBC), we sought to determine the antitumor effects of selinexor in vitro and in vivo. Methods Twenty-six...

Full description

Bibliographic Details
Main Authors: Natalia Paez Arango, Erkan Yuca, Ming Zhao, Kurt W. Evans, Stephen Scott, Charissa Kim, Ana Maria Gonzalez-Angulo, Filip Janku, Naoto T. Ueno, Debu Tripathy, Argun Akcakanat, Aung Naing, Funda Meric-Bernstam
Format: Article
Language:English
Published: BMC 2017-08-01
Series:Breast Cancer Research
Subjects:
Breast cancer
Selinexor
XPO1
PDX
TNBC
Online Access:http://link.springer.com/article/10.1186/s13058-017-0878-6

Internet

http://link.springer.com/article/10.1186/s13058-017-0878-6

Similar Items